The biopharma world – and markets – spent Thursday evening reacting as the FDA gave the green light to only its third-ever drug for ALS, Amylyx’s AMX0035.
If you are not happy with the results below please do another search
50 search results for:
Intercept Pharmaceuticals Inc. said on Friday its treatment for patients with advanced liver scarring due to non-alcoholic steatohepatitis (NASH) failed to meet the main goal of a late-stage study, sending its shares down as much as 21%.
As it gears up to launch several new products in the coming months, Moderna has created a new leadership role and onboarded an industry veteran, the company announced Thursday.
Two struggling Boston-based gene therapy companies – Solid Biosciences and AavantiBio – announced Friday they are merging to develop a portfolio of neuromuscular and cardiac programs, initially focusing on a lead candidate to treat Duchenne muscular dystrophy.
Amylyx Pharmaceuticals Inc. said on Friday it has set the list price of its newly approved drug to slow the progression of amyotrophic lateral sclerosis (ALS) at about $158,000 per year in the United States.
Cholera cases have surged this year, especially in places of poverty and conflict, with outbreaks reported in 26 countries and fatality rates rising sharply, a World Health Organization official said on Friday.
Clear evidence this week that Eisai and Biogen’s drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer’s researchers toward a tantalizing goal – preventing dementia even before symptoms start.
Around 3.2 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday.
The FDA has approved Regeneron and Sanofi’s Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis, making it the first drug approved for this indication.
Ordaōs and NonExomics announced a research pact to develop mini-proteins, called miniPROs, for three specific difficult-to-target rare cancers.